Mangoceuticals Inc. (MGRX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
15110 DALLAS PKWY, SUITE 600 DALLAS, TX 75248 |
| State of Incorp. | TX |
| Fiscal Year End | December 31 |
| Industry (SIC) | 809 - Miscellaneous Health And Allied Services, Not (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 59 | 739 | |||
| Cash and cash equivalent | 59 | 739 | |||
| Inventory, net of allowances, customer advances and progress billings | 19 | ||||
| Inventory | 19 | ||||
| Deposits current assets | 17 | ||||
| Other undisclosed current assets | 61 | ||||
| Total current assets: | 76 | 818 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 59 | 119 | |||
| Property, plant and equipment | 3 | 96 | |||
| Intangible assets, net (including goodwill) | 15,233 | ||||
| Intangible assets, net (excluding goodwill) | 15,233 | ||||
| Other undisclosed noncurrent assets | 17 | ||||
| Total noncurrent assets: | 15,295 | 232 | |||
| TOTAL ASSETS: | 15,371 | 1,051 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities, including: | 838 | 141 | |||
| Accrued liabilities | 7 | ||||
| Other undisclosed accounts payable and accrued liabilities | 838 | 134 | |||
| Debt | 150 | ||||
| Other liabilities | 373 | ||||
| Other undisclosed current liabilities | 65 | 70 | |||
| Total current liabilities: | 1,425 | 211 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 65 | ||||
| Operating lease, liability | 65 | ||||
| Total noncurrent liabilities: | 65 | ||||
| Total liabilities: | 1,425 | 276 | |||
| Equity | |||||
| Equity, attributable to parent, including: | 13,946 | 775 | |||
| Common stock | 0 | 2 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (1,150) | ||||
| Additional paid in capital | 35,588 | 12,001 | |||
| Accumulated other comprehensive loss | (10) | ||||
| Accumulated deficit | (20,807) | (11,228) | |||
| Other undisclosed equity, attributable to parent | 324 | ||||
| Equity, attributable to noncontrolling interest | (1) | ||||
| Total equity: | 13,945 | 775 | |||
| TOTAL LIABILITIES AND EQUITY: | 15,371 | 1,051 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Revenues | 616 | 731 | ||
| Cost of revenue | (93) | (155) | ||
| Other undisclosed gross profit | (143) | (145) | ||
| Gross profit: | 380 | 432 | ||
| Operating expenses | (8,352) | (9,650) | ||
| Operating loss: | (7,972) | (9,219) | ||
| Nonoperating income (expense) | (735) | 6 | ||
| Other nonoperating income | 6 | |||
| Interest and debt expense | (14) | |||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | ||||
| Loss from continuing operations before equity method investments, income taxes: | (8,721) | (9,212) | ||
| Other undisclosed income from continuing operations before income taxes | 14 | |||
| Net loss: | (8,707) | (9,212) | ||
| Net income attributable to noncontrolling interest | 1 | |||
| Net loss available to common stockholders, diluted: | (8,706) | (9,212) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Net loss: | (8,707) | (9,212) | ||
| Other undisclosed comprehensive loss | (10) | |||
| Comprehensive loss: | (8,717) | (9,212) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 1 | |||
| Comprehensive loss, net of tax, attributable to parent: | (8,716) | (9,212) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.